Press Release

Bryan, Garnier & Co initiates coverage of Hybrigenics with a target price of €2.6

Paris, March 29, 2012 - Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the initiation of coverage of its stock by the investment bank Bryan, Garnier & Co with a target price of €2.6.

The full Bryan, Garnier & Co report can be found under Corporate / Investor Relations / Press

Releases on the Hybrigenics website.

About Hybrigenics - www.hybrigenics.com

Hybrigenics is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol is currently being studied in a clinical trial for the treatment of moderate-to-severe psoriasis. Oral inecalcitol is also planned to be tested in chronic lymphocytic leukemia patients. Oral inecalcitol has already shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.
Hybrigenics Services SAS, a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

***

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG

Hybrigenics Rémi Delansorne CEO

Tel.: +33 (0)1 58 10 38 00 investors@hybrigenics.com

NewCap.

Financial communication

Axelle Vuillermet / Pierre Laurent Tel.: +33 (0)1 44 71 94 94 hybrigenics@newcap.fr

1/1

distributed by

This press release was issued by Hybrigenics SA and was initially posted at http://www.hybrigenics.com/images/stories/corporate/_download/2012/pr_note%20bg_final_veng.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-29 10:17:15 AM. The issuer is solely responsible for the accuracy of the information contained therein.